LOUISVILLE, Kentucky, May 8, 2026, 19:04 EDT
- Humana jumped 11.27% to finish at $274.96 on Friday, building on gains across managed-care names.
- Just two days after CVS boosted its 2026 profit outlook—citing tighter reins on medical costs—the move follows.
- Humana’s 2026 outlook remains squeezed, with Medicare Star Ratings and limited funding both weighing on the forecast.
Shares of Humana Inc. surged 11.27% on Friday, finishing at $274.96. Investors zeroed in on cost trends across the U.S. managed-care space, driving the Medicare insurer’s stock sharply higher. HUM had ended Thursday at $247.12, according to Humana’s historical prices.
This hits hard for Humana, a company deeply tied to Medicare Advantage—the government-backed insurance program for seniors and people with disabilities. Here, even a slight uptick in medical expenses, tweaks to plan benefits or shifts in reimbursement rates from Washington can swing profits fast.
That move followed CVS Health’s decision to lift its 2026 profit outlook on Wednesday, citing tighter controls on medical costs in its government-backed plans—Aetna included. CVS shares climbed on Friday, with UnitedHealth Group and Elevance Health logging more modest advances. The action kept attention on the group as a whole, not just Humana.
Humana’s first-quarter revenue hit $39.65 billion, up from $32.11 billion last year, with more members in its Medicare businesses and higher Medicare Advantage premiums boosting the top line. Still, adjusted earnings dropped to $10.31 per share versus $11.58, and GAAP EPS declined to $9.83 from $10.30.
The company posted an insurance segment benefit ratio of 89.4%. That figure—reflecting the proportion of premium revenue used for medical care—remains a key metric, providing a snapshot of how much latitude the insurer has for overhead and profit.
Humana stuck to its full-year adjusted earnings guidance—still at a minimum of $9 per share—but trimmed its GAAP earnings outlook to no less than $8.36 per share, down from the earlier $8.89. The company pointed to a drop in 2026, citing year-over-year pressure from Star Ratings, Medicare’s quality grades that shape bonus payments for insurers.
Chief Executive Jim Rechtin described the quarter as a “solid start to the year,” noting improvements in both customer experience and care quality. Humana is sticking with its forecast for roughly 25% growth in individual Medicare Advantage membership by 2026. Humana Health Policy Center
The recent rally hasn’t wiped out concerns for the remainder of the year. Cantor Fitzgerald’s Sarah James flagged to Reuters that Humana is showing “signals that the back-half of the year could be difficult to manage” following its earnings. Morningstar’s Julie Utterback added that investors might have expected a more ambitious 2026 outlook, given the strong opening months. Reuters
Humana continues to flag a gap between Medicare Advantage payment rates and what it’s spending on care. According to Reuters, Rechtin noted that while medical service usage and overall costs are tracking with forecasts, the split between these costs and federal reimbursements has grown compared to last year.
Washington’s stance isn’t quite as tough as it looked back in January. The Centers for Medicare & Medicaid Services, in April, projected that 2027 Medicare Advantage payments will climb 2.48% on average—translating to an increase of more than $13 billion. That’s a much bigger bump than the 0.09% rise floated earlier.
CVS tossed another number into the mix with its latest update. The company attributed the improved outlook to tighter control over Aetna’s medical costs, while CFO Brian Newman told Reuters that forecasting accuracy is getting a boost. Leerink’s Michael Cherny labeled the quarter “very strong,” Reuters also noted. Reuters
Still, Humana’s options remain limited. Should medical utilization climb in the back half, or benefit reductions knock down sign-ups, and if neither Star Ratings nor 2027 funding make up for claims expenses, Friday’s rally might not last. The company’s already flagged it will tweak benefits if that’s what it takes to keep margins intact.
